| EMA Number | (Invented) name | Strength | Pharmaceutical Form | Route of Administration | Immediate Packaging | Content (concentration) | Pack size |
|---|---|---|---|---|---|---|---|
| EU/1/24/1807/001 | Incellipan | --[1] | Suspension for injection | Intramuscular use | pre-filled syringe (glass) | 0.5 ml | 10 pre-filled syringes |

--[1]

One dose (0.5 ml) contains:
Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*:
A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms**
* propagated in Madin Darby Canine Kidney (MDCK) cells
** expressed in micrograms haemagglutinin.
Adjuvant MF59C.1 containing:

| | |
|---|---|
| squalene | 9.75 milligrams |
| polysorbate 80 | 1.175 milligrams |
| sorbitan trioleate | 1.175 milligrams |
| sodium citrate | 0.66 milligrams |
| citric acid | 0.04 milligrams |

**Annex IV**

**Conclusions on the granting of the conditional marketing authorisation presented by the European Medicines Agency**

**Conclusions presented by the European Medicines Agency on:**

- **Conditional marketing authorisation**

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.